The FDA has granted Coya 302 a fast-track designation for ALS, according to a press release from Coya Therapeutics. “ALS is a ...

Fast-track status is intended to speed the development and review of treatments for serious conditions with unmet medical needs. It will allow Spinogenix to have more frequent interactions with the ...

COYA 302, an injection therapy in development for the treatment of ALS, has been awarded fast track status by the U.S. Food and Drug Administration. The therapy aims to slow ALS progression by ...

The FDA granted Fast Track designation to the investigational biologic combination therapy COYA 302 for amyotrophic lateral sclerosis treatment.

Using advanced genetic and spatial analysis techniques, researchers discovered evidence that ALS unfolds through a ...